{"id":841591,"date":"2026-10-14T16:53:01","date_gmt":"2026-10-14T16:53:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=841591"},"modified":"2026-10-14T16:53:01","modified_gmt":"2026-10-14T16:53:01","slug":"type-1-diabetes-pipeline-gains-momentum-85-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/type-1-diabetes-pipeline-gains-momentum-85-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight_841591.html","title":{"rendered":"Type 1 Diabetes Pipeline Gains Momentum: 85+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/10\/1791965904.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Type 1 Diabetes Pipeline Gains Momentum: 85+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/10\/1791965904.jpg\" alt=\"Type 1 Diabetes Pipeline Gains Momentum: 85+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight\" width=\"225\" height=\"118\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Type 1 Diabetes clinical trial analysis report delivers important insights into ongoing research of 85+ pipeline Type 1 Diabetes drugs, clinical strategies, upcoming therapeutics, and commercial analysis.<\/div>\n<p style=\"text-align: justify;\"><strong>(Albany, US) On October 14, 2026 &#8211; <\/strong>DelveInsight&rsquo;s, &ldquo;<strong><em>Type 1 Diabetes Pipeline Insight, 2026<\/em><\/strong>&rdquo; report provides comprehensive insights about 85+ companies and 100+ pipeline drugs in Type 1 Diabetes pipeline landscape. It covers the Type 1 Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Type 1 Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about our innovative pipeline today! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Type 1 Diabetes Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>On October 13, 2026<\/strong>&#8211; <strong><em>SAB Bio therapeutics<\/em><\/strong> announced that the U.S. FDA had granted Fast Track designation to SAB-142, an investigational immunotherapy being developed to potentially modify disease progression in people with newly diagnosed Stage 3 Type 1 Diabetes. SAB-142 is being evaluated in the Phase 2b SAFEGUARD study, with topline results anticipated in the second half of 2027.<\/li>\n<li><strong><em>On October 12, 2026 &ndash; Breakthrough T1D<\/em><\/strong> announced the conclusion of its inaugural Clinical &amp; Research Congress, held to highlight advances in Type 1 Diabetes research and bring together clinicians, researchers, industry leaders, and advocates working toward improved disease management and potential cures.<\/li>\n<li><strong><em>On October 5, 2026 &ndash; vTv Therapeutics<\/em><\/strong> announced completion of enrollment in its Phase 3 CATT1 study evaluating cadisegliatin, an investigational oral, liver-selective glucokinase activator intended to be used alongside insulin for Type 1 Diabetes. A total of 166 patients were randomized, with topline results expected in mid-2027.<\/li>\n<li>DelveInsight&rsquo;s Type 1 Diabetes pipeline report depicts a robust space with 85+ active players working to develop 100+ pipeline therapies for Type 1 Diabetes treatment.<\/li>\n<li>The leading Type 1 Diabetes Companies such as <strong><em>Lilly, vTv Therapeutics, Oramed, Ltd., Novo Nordisk A\/S, SAb Biotherapeutics, Inc., Op-T LLC, Seraxis, Creative Medical Technology Holdings Inc, COUR Pharmaceutical Development Company, Inc., Sanofi, Zucara Therapeutics Inc., Otsuka Pharmaceutical Factory, Inc., Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals, Immunocore Ltd<\/em><\/strong>. and others.<\/li>\n<li>Promising Type 1 Diabetes Pipeline Therapies such as <strong><em>Subetta, ORMD 0801, LY900014, Ladarixin, Technosphere Insulin, BMF-219, ASP1941, VX-264, Zenapax, Ipragliflozin, Glargine, LY2963016<\/em><\/strong> and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Stay informed about the cutting-edge advancements in Type 1 Diabetes treatments @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Type 1 Diabetes Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">The Type 1 Diabetes Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Type 1 Diabetes Pipeline Report also highlights the unmet needs with respect to the Type 1 Diabetes.<\/p>\n<p style=\"text-align: justify;\"><strong>Type 1 Diabetes Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Type 1 diabetes is a chronic autoimmune disease in which the body&rsquo;s immune system mistakenly attacks and destroys the insulin-producing beta cells of the pancreas. As a result, the body produces little or no insulin, a hormone required to allow glucose to enter cells for energy production. The disease commonly develops in children, adolescents, and young adults, although it can occur at any age. Symptoms often appear suddenly and may include excessive thirst, frequent urination, weight loss, fatigue, and blurred vision. Without insulin therapy, type 1 diabetes can lead to life-threatening complications such as diabetic ketoacidosis.<\/p>\n<p style=\"text-align: justify;\"><strong>Type 1 Diabetes Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Baricitinib: Lilly<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Baricitinib is an oral Janus kinase (JAK) inhibitor developed by Eli Lilly and Company in collaboration with Incyte. Baricitinib works by selectively inhibiting JAK1 and JAK2 signaling pathways involved in autoimmune inflammation, thereby reducing immune-mediated destruction of pancreatic beta cells and helping preserve endogenous insulin production. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Type 1 Diabetes.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Cadisegliatin: vTv Therapeutics<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Cadisegliatin is an investigational oral, liver-selective glucokinase activator being developed for adjunctive treatment of Type 1 Diabetes (T1D). The drug is designed to activate hepatic glucokinase and improve glucose utilization and glycogen storage in the liver without directly stimulating pancreatic insulin secretion, thereby helping reduce hyperglycemia and improving glycemic control while potentially lowering the risk of hypoglycemia and ketoacidosis in patients using insulin therapy. Cadisegliatin received the U.S. FDA Breakthrough Therapy Designation for Type 1 Diabetes. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Type 1 Diabetes.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>ZT-01: Zucara Therapeutics Inc.<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">ZT-01 is an investigational once-daily oral therapy being developed for people with Type 1 Diabetes (T1D), particularly to reduce nocturnal hypoglycemia associated with insulin treatment. The drug is a selective inhibitor of the somatostatin receptor type 2 (SSTR2), designed to restore the body&rsquo;s natural glucagon response during hypoglycemia, by blocking SSTR2 signaling. ZT-01 enhances glucagon secretion from pancreatic alpha cells, thereby helping prevent dangerous low blood glucose episodes without interfering with insulin therapy. ZT-01 has received FDA Fast Track Designation for the prevention of severe hypoglycemia in Type 1 Diabetes. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Type 1 Diabetes.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>IMC-S118AI: Immunocore Ltd<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">IMC-S118AI is an investigational autoimmune therapy being developed for Type 1 Diabetes (T1D) as part of the company&rsquo;s ImmTAAI (Immune mobilising monoclonal TCRs Against AutoImmune disease) platform. IMC-S118AI is designed as a disease-modifying therapy that specifically targets pancreatic beta cells by recognizing a peptide from pre-pro-insulin presented by HLA-A02 on beta cells and delivering a PD-1 agonist effector signal to suppress pathogenic autoreactive T cells locally, thereby reducing immune-mediated beta-cell destruction. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Type 1 Diabetes.<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about Type 1 Diabetes Drugs opportunities in our groundbreaking Type 1 Diabetes research and development projects @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Type 1 Diabetes Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The Type 1 Diabetes Pipeline Report provides insights into<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Type 1 Diabetes with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Type 1 Diabetes Treatment.<\/li>\n<li>Type 1 Diabetes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Type 1 Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Type 1 Diabetes market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Type 1 Diabetes Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>Lilly, vTv Therapeutics, Oramed, Ltd., Novo Nordisk A\/S, SAb Biotherapeutics, Inc., Op-T LLC, Seraxis, Creative Medical Technology Holdings Inc, COUR Pharmaceutical Development Company, Inc., Sanofi, Zucara Therapeutics Inc., Otsuka Pharmaceutical Factory, Inc., Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals, Immunocore Ltd<\/em><\/strong>. and others.<\/p>\n<p style=\"text-align: justify;\"><strong>Type 1 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Intra-articular<\/li>\n<li>Intraocular<\/li>\n<li>Intrathecal<\/li>\n<li>Intravenous<\/li>\n<li>Ophthalmic<\/li>\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical<\/li>\n<li>Transdermal<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Type 1 Diabetes Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oligonucleotide<\/li>\n<li>Peptide<\/li>\n<li>Small molecule<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Discover the latest advancements in Type 1 Diabetes treatment by visiting our website @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Type 1 Diabetes Market Drivers and Barriers, and Future Perspectives<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Type 1 Diabetes Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Type 1 Diabetes Companies- <strong><em>Lilly, vTv Therapeutics, Oramed, Ltd., Novo Nordisk A\/S, SAb Biotherapeutics, Inc., Op-T LLC, Seraxis, Creative Medical Technology Holdings Inc, COUR Pharmaceutical Development Company, Inc., Sanofi, Zucara Therapeutics Inc., Otsuka Pharmaceutical Factory, Inc., Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals, Immunocore Ltd<\/em><\/strong>. and others<\/li>\n<li>Type 1 Diabetes Pipeline Therapies- <strong><em>Subetta, ORMD 0801, LY900014, Ladarixin, Technosphere Insulin, BMF-219, ASP1941, VX-264, Zenapax, Ipragliflozin, Glargine, LY2963016<\/em><\/strong> and others.<\/li>\n<li>Type 1 Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Type 1 Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Read the full details of Type 1 Diabetes Pipeline on our website, @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Type 1 Diabetes Emerging Drugs and Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Type 1 Diabetes: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Type 1 Diabetes&ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Preregistration)<\/li>\n<li>Baricitinib: Lilly<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>ZT-01: Zucara Therapeutics Inc.<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I\/II)<\/li>\n<li>IMC-S118AI: Immunocore Ltd<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Type 1 Diabetes Key Companies<\/li>\n<li>Type 1 Diabetes Key Products<\/li>\n<li>Type 1 Diabetes- Unmet Needs<\/li>\n<li>Type 1 Diabetes- Market Drivers and Barriers<\/li>\n<li>Type 1 Diabetes- Future Perspectives and Conclusion<\/li>\n<li>Type 1 Diabetes Analyst Views<\/li>\n<li>Type 1 Diabetes Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=type-1-diabetes-pipeline-gains-momentum-85-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/type-1-diabetes-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/type-1-diabetes-pipeline-insight<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=type-1-diabetes-pipeline-gains-momentum-85-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Type 1 Diabetes clinical trial analysis report delivers important insights into ongoing research of 85+ pipeline Type 1 Diabetes drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) On October 14, 2026 &#8211; DelveInsight&rsquo;s, &ldquo;Type 1 Diabetes Pipeline &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/type-1-diabetes-pipeline-gains-momentum-85-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight_841591.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,420,413],"tags":[],"class_list":["post-841591","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/841591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=841591"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/841591\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=841591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=841591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=841591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}